Pru Pension AXA Framlington Health Ser A

Essentials Portfolio Analysis Background Data Performance View PDF Factsheet

Performance

Discrete Performance - to last month end

30/04/12 to 30/04/13 30/04/11 to 30/04/12 30/04/10 to 30/04/11 30/04/09 to 30/04/10 30/04/08 to 30/04/09
Fund 25.52% 6.02% 12.53% 30.39% -
Sector 10.48% -1.53% 4.56% 24.00% -11.07%
Rank 39/380 49/338 22/293 58/204 -
Quartile 1 1 1 2 -

Annualised Performance

3Y 5Y 10Y
Fund 14.41% - -
Sector 4.39% 4.64% 7.25%
Rank 9/293 - -
Quartile 1 - -

Top 10 Holdings

Stock % Weight
Express Scripts Holding 3.05
Gilead Sciences 2.79
UnitedHealth Group 2.72
Celgene Corp. 2.65
Covidien 2.52
Roche Holding AG Part. Cert. 2.32
Allergan 2.23
McKesson Corp. 2.23
Merck & Co. 2.00
Pfizer 1.99
Total 24.51

Fund Aims

The investment strategy of the fund is to purchase units in the AXA Framlington Health Fund. That fund aims to achieve capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.

Fund Manager

Gemma Game manager for 1 years and 10 months

Photo of Gemma Game Gemma joined AXA Framlington in October 2007 as a Senior Portfolio Manager. Prior to this Gemma was a vice president at BlackRock, where she was a portfolio manager on the Global Equities Team covering the healthcare sector. Gemma began her career at Merrill Lynch Investment Managers (MLIM), which subsequently merged with BlackRock in October 2006. She joined MLIM in 2001 and worked on the Global Equities Team from 2002-2006 with responsibility for investment in the healthcare sector. Gemma became a portfolio manager in 2005 and she continued her responsibilities as portfolio man-ager and healthcare specialist on the Global Team following the merger of BlackRock and MLIM. Gemma is a CFA Charterholder (2004) and has an MA (Hons) in Natural Sciences from Cambridge University (1998-2001).

Fund Overview

Bid (22/05/2013) 217.50
Offer (22/05/2013) 229.00
Fund size £0.59m
Underlying Fund size £313.91m
Number of holdings 86
Annual management charge 1.80%
Launch date 20/10/2008

Equity Sector Allocation

FTSE/ICB Supersector % Weight
Health Care 87.62
Retail 7.26
Cash and Equivalents 1.55
Non-Classified 1.28
Technology 1.24
Industrial Goods & Services 1.06
Portfolio data accurate as at: 30/04/13

Important Information

Source of portfolio data: FundsLibrary. Source of performance data: Financial Express. Please remember that past performance is not a reliable indicator of future performance. The figures shown are intended only to demonstrate performance history of the fund and take no account of product charges. Fund performance is based upon the movement of the daily price. Performance figures show total return with gross income reinvested in GBP. The value of your investment may go down as well as up and the fund value at retirement may be less than the payments you have made. This data is for information purposes only. If there is information or terminology included that you would like to discuss, then please contact an adviser. Investors should refer to their policy documentation and supporting brochures for fund availability, investment strategy, any product information and charges. Every care has been taken in populating this output, however it must be appreciated that neither Funds Library, Prudential nor their sources guarantee the accuracy, adequacy or completeness of this report or make any warranties regarding results from it's usage. The registered office of Prudential is at Laurence Pountney Hill, London EC4R 0HH. Registered number 15454. The registered office of Prudential is at Laurence Pountney Hill, London EC4R 0HH. Registered number 15454.

Asset Allocation

pie chart
  International Equities 92.90%
  UK Equities 5.56%
  Cash and Equivalents 1.55%

Equity Sector Breakdown

Expand allCollapse all
Industry Supersector Sector Subsector
 
 Consumer Services 7.26% - - -
 
 Retail - 7.26% - -
 
 Food & Drug Retailers - - 7.26% -
 
 Drug Retailers - - - 7.26%
 
 Health Care 87.62% - - -
 
 Health Care - 87.62% - -
 
 Pharmaceuticals & Biotechnology - - 44.07% -
 
 Pharmaceuticals - - - 26.96%
 
 Biotechnology - - - 17.11%
 
 Health Care Equipment & Services - - 43.55% -
 
 Health Care Providers - - - 22.02%
 
 Medical Equipment - - - 14.83%
 
 Medical Supplies - - - 6.70%
 
 Industrials 1.06% - - -
 
 Industrial Goods & Services - 1.06% - -
 
 Support Services - - 1.06% -
 
 Waste & Disposal Services - - - 1.06%
 
 Technology 1.24% - - -
 
 Technology - 1.24% - -
 
 Software & Computer Services - - 1.24% -
 
 Software - - - 1.24%
 
 Non-Classified 1.28% - - -
 
 Cash and Equivalents 1.55% - - -

Regional Allocation

pie chart
  North America 76.76%
  Developed Europe - Excl UK 11.48%
  UK 5.56%
  Middle East & Africa 2.27%
  Cash and Equivalents 1.55%
  Japan 1.20%
  South & Central America 1.19%
pie chart
  Non-debt 97.10%
  Cash 2.24%
  Euro 0.66%

Regional Breakdown

Expand allCollapse all
Region Country
 
 North America 76.76% -
 
 United States - 76.04%
 
 Canada - 0.72%
 
 Developed Europe - Excl UK 11.48% -
 
 Switzerland - 4.49%
 
 Germany - 3.27%
 
 Ireland - 3.07%
 
 Netherlands - 0.51%
 
 Sweden - 0.14%
 
 UK 5.56% -
 
 United Kingdom - 5.56%
 
 Middle East & Africa 2.27% -
 
 Israel - 1.28%
 
 South Africa - 0.99%
 
 Cash and Equivalents 1.55% -
 
 Japan 1.20% -
 
 Japan - 1.20%
 
 South & Central America 1.19% -
 
 Brazil - 1.19%

Breakdown By Market Cap (%)

Mega
 
 
33.99%
Large
 
 
30.34%
Medium
 
 
18.39%
Small
 
 
12.86%
Micro
 
 
1.07%
Non-Classified
 
 
1.79%
Bonds
 
 
0.00%
Cash
 
 
1.55%

Top 10 Holdings

Stock % Weight Sector Country
1 Express Scripts Holding 3.05% Health Care United States
2 Gilead Sciences 2.79% Health Care United States
3 UnitedHealth Group 2.72% Health Care United States
4 Celgene Corp. 2.65% Health Care United States
5 Covidien 2.52% Health Care Ireland
6 Roche Holding AG Part. Cert. 2.32% Health Care Switzerland
7 Allergan 2.23% Health Care United States
8 McKesson Corp. 2.23% Retail United States
9 Merck & Co. 2.00% Health Care United States
10 Pfizer 1.99% Health Care United States

Dual Aspect Equity Analysis

UK Equities Int'l Equities UK Bonds Int'l Bonds UK Gilts Managed Funds Property Other Cash & Equiv Total
Basic Materials - - - - - - - - - -
Consumer Goods - - - - - - - - - -
Consumer Services - 7.26% - - - - - - - 7.26%
Financials - - - - - - - - - -
Health Care 5.56% 82.06% - - - - - - - 87.62%
Industrials - 1.06% - - - - - - - 1.06%
Oil & Gas - - - - - - - - - -
Technology - 1.24% - - - - - - - 1.24%
Telecommunications - - - - - - - - - -
Utilities - - - - - - - - - -
Property - - - - - - - - - -
Cash and Equivalents - - - - - - - - 1.55% 1.55%
Managed Funds - - - - - - - - - -
Bonds - - - - - - - - - -
Non-Classified - 1.28% - - - - - - - 1.28%
Commodities - - - - - - - - - -
Alternative Trading Strategies - - - - - - - - - -
Portfolio data accurate as at: 30/04/13

Important Information

The Industry Classification Benchmark is a joint product of FTSE International Limited and Dow Jones & Company, Inc and has been licensed for use. This data is for information purposes only. If there is information or terminology included that you would like to discuss, then please contact an adviser. Investors should refer to their policy documentation and supporting brochures for fund availability, investment strategy, any product information and charges. Every care has been taken in populating this output, however it must be appreciated that neither Funds Library, Prudential nor their sources guarantee the accuracy, adequacy or completeness of this report or make any warranties regarding results from its usage.

Identification Codes

Sedol Code B3BW135
Mex Code PUAFRH
Isin Code GB00B3BW1350
Citi Code D9L2

Charges

Annual management charge 1.80%

Aims and Benchmark

Benchmark MSCI World Healthcare
ABI Sector Specialist
Aims The investment strategy of the fund is to purchase units in the AXA Framlington Health Fund. That fund aims to achieve capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.

Fund Background

Launch date 20/10/2008

Ratings

OBSR OBSR rating of Bronze
FE Crown Crown Rating of 3